Alpana Naresh, Ph.D.

Chief Manufacturing Officer at Hinge Bio, Inc.

Speaker

Alpana Naresh has been at Hinge Bio since March 2025 and is responsible for development, manufacturing, regulatory filing and CMC strategy for Hinge Bio's GEM-DIMER^TM multi-specific products. She manages CMC operations for clinical supply of HB2198, a novel tetravalent bispecific antibody with two Fc domains for B cell mediated diseases.

Before joining Hinge Bio, Alpana was Executive Director of CMC Operations at Harpoon Therapeutics, Inc and subsequently Merck, following Merck’s acquisition of Harpoon. At Harpoon, Alpana worked on the development, transfer, and manufacturing of novel T-cell engager molecules (Tri-specific T cell Activating Construct (TriTAC®) platform and ProTriTAC™ platform) for clinical studies of various cancers.

Previous positions included roles at Boehringer Ingelheim, JSR Life Sciences, Sutro Biopharma, Genitope, and post-doctoral fellowships at Stanford University and University of Virginia. Dr. Naresh is a collaborative, results driven biotechnology professional with more than 25 years of research and development experience with multiple biomolecules including immunoglobulins as personalized vaccines for cancer; monoclonal antibodies; bispecific antibodies; trispecific antibody derived modalities.

Dr. Naresh received her Masters in Biotechnology from CCSHAU and Doctor of Philosophy in Biotechnology from IMTech, Chandigarh and was post-doctoral fellow at Stanford University in Professor Cleary’s lab.